Richard Newcomb
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Richard Newcomb has a total of 230 co-authors. Here are the top co-authors by number of shared publications:
Areej El-Jawahri
MGB Cancer Institute, United States
16 shared publications- Yi-Bin Chen
Massachusetts General Hospital
13 shared publications - Areej El-Jawahri
Massachusetts General Hospital, Boston, MA
12 shared publications - Zachariah DeFilipp
Hematopoietic Cell Transplant and Cellular Therapy Program, Massachusetts General Hospital, Boston, USA
12 shared publications - Hermioni L. Amonoo
Department of Supportive Oncology, Dana-Farber Cancer Institute, Boston, MA
9 shared publications - Anna Barata
Cancer Center, Massachusetts General Hospital
7 shared publications
Latest Publications
- Open Access
- 2 October 2026
- Published by American Society of Hematology in Blood Advances
An Electronic Frailty Index Is Associated with Outcomes in Older Adults Receiving CAR-T Therapy
Predicting outcomes for older adults undergoing Chimeric Antigen Receptor T-cell (CAR-T) therapy is critical. Frailty is associated with poor outcomes, but can be difficult to measure in clinical practice. We retrospectively analyzed patients age ≥65 years receiving commercial CAR-T at Mass General Brigham for multiple myeloma and B-cell non-Hodgkin lymphoma. We calculated an electronic frailty index (eFI), a validated, automated frailty score (0.3=very frail). We evaluated associations of eFI (robust/prefrail vs frail vs very frail) with overall survival (OS), event-free (death, progression, or new treatment) survival (EFS), toxicity (cytokine release syndrome (CRS) and/or immune effector cell-associated neurotoxicity syndrome (ICANS)), and days alive and out of hospital in the first 30 days (DAOH) using regression models controlling for confounders. Among 260 patients (median age: 73 years [range 65-91]), 10% were robust, 25% prefrail, 28% frail, and 37% very frail. In multivariable analyses, being frail was not associated with OS (hazard ratio [HR] 1.22, p=0.45) or EFS (HR=1.39, p=0.14), but very frail patients had significantly worse OS (HR=1.64, p<0.05) and EFS (HR=2.02, p<0.01). Both frail and very frail patients, respectively, had higher odds of grade 3+ toxicity (odds ratio [OR]=3.28, p<0.05; OR=4.84, p<0.01) and fewer DAOH (β= -2.37, p = 0.03; β= -3.79, p<0.01). The eFI identifies frail and very frail patients with higher risk for grade 3+ CRS/ICANS and increased healthcare utilization. Very frail patients are especially high-risk with poor OS and EFS. The eFI holds promise as an automated CAR-T risk-stratification tool.
- 2 October 2026
- Published by American Society of Hematology in Blood Advances
Open AccessAn Electronic Frailty Index Is Associated with Outcomes in Older Adults Receiving CAR-T Therapy
Predicting outcomes for older adults undergoing Chimeric Antigen Receptor T-cell (CAR-T) therapy is critical. Frailty is associated with poor outcomes, but can be difficult to measure in clinical practice. We retrospectively analyzed patients age ≥65 years receiving commercial CAR-T at Mass General Brigham for multiple myeloma and B-cell non-Hodgkin lymphoma. We calculated an electronic frailty index (eFI), a validated, automated frailty score (0.3=very frail). We evaluated associations of eFI (robust/prefrail vs frail vs very frail) with overall survival (OS), event-free (death, progression, or new treatment) survival (EFS), toxicity (cytokine release syndrome (CRS) and/or immune effector cell-associated neurotoxicity syndrome (ICANS)), and days alive and out of hospital in the first 30 days (DAOH) using regression models controlling for confounders. Among 260 patients (median age: 73 years [range 65-91]), 10% were robust, 25% prefrail, 28% frail, and 37% very frail. In multivariable analyses, being frail was not associated with OS (hazard ratio [HR] 1.22, p=0.45) or EFS (HR=1.39, p=0.14), but very frail patients had significantly worse OS (HR=1.64, p<0.05) and EFS (HR=2.02, p<0.01). Both frail and very frail patients, respectively, had higher odds of grade 3+ toxicity (odds ratio [OR]=3.28, p<0.05; OR=4.84, p<0.01) and fewer DAOH (β= -2.37, p = 0.03; β= -3.79, p<0.01). The eFI identifies frail and very frail patients with higher risk for grade 3+ CRS/ICANS and increased healthcare utilization. Very frail patients are especially high-risk with poor OS and EFS. The eFI holds promise as an automated CAR-T risk-stratification tool.
- 30 June 2026
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 61 (9) , 1-3
A multimodal sexual health intervention among hematopoietic stem cell transplant recipients: mediating effects on quality of life and mood
- 30 June 2026
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 61 (9) , 1-3
A multimodal sexual health intervention among hematopoietic stem cell transplant recipients: mediating effects on quality of life and mood
- 24 April 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- p. OP2501370
Donor Selection in the Post-Transplant Cyclophosphamide Era: Do the Little Things Matter?
- 24 April 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- p. OP2501370
Donor Selection in the Post-Transplant Cyclophosphamide Era: Do the Little Things Matter?
- 24 February 2026
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 32 (6) , 754.e1-754.e8
Association Between Patient-Reported Outcomes Prior to Chimeric Antigen Receptor (CAR) T-Cell Therapy and Clinical Outcomes
- 24 February 2026
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 32 (6) , 754.e1-754.e8
Association Between Patient-Reported Outcomes Prior to Chimeric Antigen Receptor (CAR) T-Cell Therapy and Clinical Outcomes
- 20 August 2025
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 43 (24) , 2700-2711
Multisite Randomized Trial of Inpatient Palliative Care Intervention for Patients Undergoing Hematopoietic Stem Cell Transplantation
PURPOSE: Patients undergoing hematopoietic stem cell transplantation (HSCT) and their caregivers endure immense physical and psychological symptoms, which result in quality-of-life (QOL) impairments during HSCT. METHODS: We conducted a multisite randomized trial among adults undergoing autologous or allogeneic HSCT at three academic institutions. Patients were randomly assigned to an inpatient palliative care (PC) intervention or usual care. Intervention patients met with PC clinicians twice weekly during the HSCT hospitalization. Patients assigned to usual care could be referred to PC as per standard of care. We assessed QOL (patient: Functional Assessment of Cancer Therapy-Bone Marrow Transplant; caregiver: Caregiver-Oncology-QOL), depression and anxiety symptoms (Hospital-Anxiety-and-Depression-Scale), and patients' post-traumatic stress disorder (PTSD) symptoms (PTSD Checklist) at baseline, week 2, and 3 and 6 months post-HSCT. The primary end point was patients' QOL at week 2 during hospitalization when patients experience their QOL nadir. We used linear regression, adjusting for baseline scores, to evaluate the effect of the intervention on patient-reported outcomes at week 2. We used linear mixed-effect models to assess the effect of the intervention on study outcomes longitudinally. RESULTS: We enrolled 68.7% (360/524) of eligible patients between October 2018 and July 2022. Compared with those receiving usual care, patients receiving the intervention reported better QOL (adjusted mean difference [B], 6.3; SE, 0.1; P < .001), lower depression (B, –1; SE, 0.4; P = .026), and fewer PTSD symptoms (B, –1.9; SE, 0.9; P = .046) at week 2. Patient-reported anxiety did not differ significantly between groups at week 2. In longitudinal analyses, patients receiving the intervention reported a steeper decline in PTSD symptoms over 6 months post-HSCT (slope difference, –0.9; SE, 0.7; P = .012). All other patient-reported outcomes did not differ longitudinally between the groups. CONCLUSION: PC led to substantial improvements in patients' QOL, depression, and PTSD symptoms with sustained effects on PTSD symptoms up to 6 months post-HSCT.
- 20 August 2025
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 43 (24) , 2700-2711
Multisite Randomized Trial of Inpatient Palliative Care Intervention for Patients Undergoing Hematopoietic Stem Cell Transplantation
PURPOSE: Patients undergoing hematopoietic stem cell transplantation (HSCT) and their caregivers endure immense physical and psychological symptoms, which result in quality-of-life (QOL) impairments during HSCT. METHODS: We conducted a multisite randomized trial among adults undergoing autologous or allogeneic HSCT at three academic institutions. Patients were randomly assigned to an inpatient palliative care (PC) intervention or usual care. Intervention patients met with PC clinicians twice weekly during the HSCT hospitalization. Patients assigned to usual care could be referred to PC as per standard of care. We assessed QOL (patient: Functional Assessment of Cancer Therapy-Bone Marrow Transplant; caregiver: Caregiver-Oncology-QOL), depression and anxiety symptoms (Hospital-Anxiety-and-Depression-Scale), and patients' post-traumatic stress disorder (PTSD) symptoms (PTSD Checklist) at baseline, week 2, and 3 and 6 months post-HSCT. The primary end point was patients' QOL at week 2 during hospitalization when patients experience their QOL nadir. We used linear regression, adjusting for baseline scores, to evaluate the effect of the intervention on patient-reported outcomes at week 2. We used linear mixed-effect models to assess the effect of the intervention on study outcomes longitudinally. RESULTS: We enrolled 68.7% (360/524) of eligible patients between October 2018 and July 2022. Compared with those receiving usual care, patients receiving the intervention reported better QOL (adjusted mean difference [B], 6.3; SE, 0.1; P < .001), lower depression (B, –1; SE, 0.4; P = .026), and fewer PTSD symptoms (B, –1.9; SE, 0.9; P = .046) at week 2. Patient-reported anxiety did not differ significantly between groups at week 2. In longitudinal analyses, patients receiving the intervention reported a steeper decline in PTSD symptoms over 6 months post-HSCT (slope difference, –0.9; SE, 0.7; P = .012). All other patient-reported outcomes did not differ longitudinally between the groups. CONCLUSION: PC led to substantial improvements in patients' QOL, depression, and PTSD symptoms with sustained effects on PTSD symptoms up to 6 months post-HSCT.
- Open Access
- 11 August 2025
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 31 (11) , 854.e1-854.e4
Safe and Effective Addition of Ruxolitinib to Graft-versus-host Prophylaxis in Older Adults Undergoing Reduced-intensity Allogeneic Hematopoietic Cell Transplantation
- 11 August 2025
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 31 (11) , 854.e1-854.e4
Open AccessSafe and Effective Addition of Ruxolitinib to Graft-versus-host Prophylaxis in Older Adults Undergoing Reduced-intensity Allogeneic Hematopoietic Cell Transplantation
- 1 August 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Advances
- No. 2
Phase II Study of Peri- and Post-Transplant Ruxolitinib for Patients With Myelofibrosis Receiving Allogeneic Hematopoietic Cell Transplantation
PURPOSE: We conducted a phase II, multicenter trial (ClinicalTrials.gov identifier: NCT03427866 ) investigating ruxolitinib administration before, during, and after allogeneic hematopoietic cell transplantation (HCT) for patients with primary or secondary myelofibrosis (MF). The primary end point was 1-year graft-versus-host disease (GVHD)-free, relapse-free survival (GRFS). METHODS: Between 2018 and 2023, 43 participants received reduced-intensity HCT from 7/8 or 8/8 human leukocyte antigen–matched donors, with use of tacrolimus and methotrexate as GVHD prophylaxis. Participants were treated with ruxolitinib 5 mg twice a day starting on Day –14, and continued ruxolitinib until 1 year after transplant. Most participants (n = 36, 84%) had Dynamic International Prognosis Scoring System plus intermediate-2/high-risk MF and 26 (60%) were receiving ruxolitinib before HCT. Common molecular mutations before transplant included Janus kinase 2 (n = 25), CALR (n = 8), MPL (n = 5), and ASXL1 (n = 13). RESULTS: With a median follow-up of 27 months (range 1-64), 1-year GRFS was 71%. Overall survival (OS), progression-free survival, and cumulative incidence of nonrelapse mortality and disease relapse at 2 years were 82%, 72%, 12%, and 16%, respectively. The cumulative incidence of grade 3 to 4 acute GVHD at 6 months was 2.4%. Two-year moderate/severe chronic GVHD was 15%. The most common severe (grade ≥3) adverse events were hematologic in nature. In univariable analysis, spleen >20 cm before HCT (hazard ratio, 5.11, P = .04) was associated with worse OS (2-year OS: 67% v 89%, P = .015). CONCLUSION: In summary, continued ruxolitinib administration during and after HCT demonstrates safety and tolerability, and is associated with low rates of clinically significant GVHD and encouraging survival outcomes for MF.
- 1 August 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Advances
- No. 2
Phase II Study of Peri- and Post-Transplant Ruxolitinib for Patients With Myelofibrosis Receiving Allogeneic Hematopoietic Cell Transplantation
PURPOSE: We conducted a phase II, multicenter trial (ClinicalTrials.gov identifier: NCT03427866 ) investigating ruxolitinib administration before, during, and after allogeneic hematopoietic cell transplantation (HCT) for patients with primary or secondary myelofibrosis (MF). The primary end point was 1-year graft-versus-host disease (GVHD)-free, relapse-free survival (GRFS). METHODS: Between 2018 and 2023, 43 participants received reduced-intensity HCT from 7/8 or 8/8 human leukocyte antigen–matched donors, with use of tacrolimus and methotrexate as GVHD prophylaxis. Participants were treated with ruxolitinib 5 mg twice a day starting on Day –14, and continued ruxolitinib until 1 year after transplant. Most participants (n = 36, 84%) had Dynamic International Prognosis Scoring System plus intermediate-2/high-risk MF and 26 (60%) were receiving ruxolitinib before HCT. Common molecular mutations before transplant included Janus kinase 2 (n = 25), CALR (n = 8), MPL (n = 5), and ASXL1 (n = 13). RESULTS: With a median follow-up of 27 months (range 1-64), 1-year GRFS was 71%. Overall survival (OS), progression-free survival, and cumulative incidence of nonrelapse mortality and disease relapse at 2 years were 82%, 72%, 12%, and 16%, respectively. The cumulative incidence of grade 3 to 4 acute GVHD at 6 months was 2.4%. Two-year moderate/severe chronic GVHD was 15%. The most common severe (grade ≥3) adverse events were hematologic in nature. In univariable analysis, spleen >20 cm before HCT (hazard ratio, 5.11, P = .04) was associated with worse OS (2-year OS: 67% v 89%, P = .015). CONCLUSION: In summary, continued ruxolitinib administration during and after HCT demonstrates safety and tolerability, and is associated with low rates of clinically significant GVHD and encouraging survival outcomes for MF.
- 10 July 2025
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 43 (20) , 2265-2275
BMT-CARE App: A Randomized Controlled Trial of a Psychosocial Digital Application for Caregivers of Patients Undergoing Hematopoietic Stem-Cell Transplantation
PURPOSE: Family and friend caregivers of patients undergoing hematopoietic stem-cell transplantation (HSCT) struggle with immense caregiving burden, leading to substantial quality of life (QOL) impairments and psychological distress. Yet, interventions to address caregivers' needs are limited. MATERIALS AND METHODS: We conducted a randomized controlled trial of a psychosocial digital application (BMT-CARE App) versus usual care for adult caregivers of patients with hematologic malignancies undergoing HSCT. The BMT-CARE App included five modules combining psychoeducation and evidence-based behavior change strategies. Participants completed self-report measures at baseline and day 60 post-HSCT. The primary end point was QOL at day 60 assessed by the CareGiver Oncology QOL (CarGOQOL) measure. We also assessed caregiving burden (Caregiver Reaction Assessment), anxiety and depression symptoms (Hospital Anxiety and Depression Scale), and post-traumatic stress disorder (PTSD) symptoms (PTSD Checklist [PCL-5]). We used analysis of covariance adjusting for baseline scores to assess the effect of the intervention on study outcomes. RESULTS: Between February 2023 and July 2024, we enrolled 125 of 174 approached caregivers (71.8%). Participants assigned to the BMT-CARE App used the app for a median of 146.9 minutes (range, 0-384.8). At day 60, BMT-CARE App caregivers reported clinically and significantly better QOL than those assigned to usual care (adjusted means = 76.3 v 69.9, P = .006). BMT-CARE App participants also reported significantly lower caregiving burden (11.2 v 12.3, P = .023), depression (3.8 v 5.6, P = .002), and PTSD symptoms (26.1 v 31.3, P = .012). The groups did not differ significantly in anxiety symptoms at day 60. CONCLUSION: The BMT-CARE App led to significantly improved QOL, caregiving burden, depression, and PTSD symptoms among HSCT caregivers. This intervention should be tested in a multicenter study with a diverse HSCT caregiver population to determine generalizability and scalability.
- 10 July 2025
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 43 (20) , 2265-2275
BMT-CARE App: A Randomized Controlled Trial of a Psychosocial Digital Application for Caregivers of Patients Undergoing Hematopoietic Stem-Cell Transplantation
PURPOSE: Family and friend caregivers of patients undergoing hematopoietic stem-cell transplantation (HSCT) struggle with immense caregiving burden, leading to substantial quality of life (QOL) impairments and psychological distress. Yet, interventions to address caregivers' needs are limited. MATERIALS AND METHODS: We conducted a randomized controlled trial of a psychosocial digital application (BMT-CARE App) versus usual care for adult caregivers of patients with hematologic malignancies undergoing HSCT. The BMT-CARE App included five modules combining psychoeducation and evidence-based behavior change strategies. Participants completed self-report measures at baseline and day 60 post-HSCT. The primary end point was QOL at day 60 assessed by the CareGiver Oncology QOL (CarGOQOL) measure. We also assessed caregiving burden (Caregiver Reaction Assessment), anxiety and depression symptoms (Hospital Anxiety and Depression Scale), and post-traumatic stress disorder (PTSD) symptoms (PTSD Checklist [PCL-5]). We used analysis of covariance adjusting for baseline scores to assess the effect of the intervention on study outcomes. RESULTS: Between February 2023 and July 2024, we enrolled 125 of 174 approached caregivers (71.8%). Participants assigned to the BMT-CARE App used the app for a median of 146.9 minutes (range, 0-384.8). At day 60, BMT-CARE App caregivers reported clinically and significantly better QOL than those assigned to usual care (adjusted means = 76.3 v 69.9, P = .006). BMT-CARE App participants also reported significantly lower caregiving burden (11.2 v 12.3, P = .023), depression (3.8 v 5.6, P = .002), and PTSD symptoms (26.1 v 31.3, P = .012). The groups did not differ significantly in anxiety symptoms at day 60. CONCLUSION: The BMT-CARE App led to significantly improved QOL, caregiving burden, depression, and PTSD symptoms among HSCT caregivers. This intervention should be tested in a multicenter study with a diverse HSCT caregiver population to determine generalizability and scalability.